These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 22228030)

  • 1. Gastrointestinal symptoms in cancer patients with advanced disease: new methodologies, insights, and a proposed approach.
    Rangwala F; Zafar SY; Abernethy AP
    Curr Opin Support Palliat Care; 2012 Mar; 6(1):69-76. PubMed ID: 22228030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detailing of gastrointestinal symptoms in cancer patients with advanced disease: new methodologies, new insights, and a proposed approach.
    Abernethy AP; Wheeler JL; Zafar SY
    Curr Opin Support Palliat Care; 2009 Mar; 3(1):41-9. PubMed ID: 19365160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
    Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
    Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients.
    Kitamura H; Takahashi A; Hotta H; Kato R; Kunishima Y; Takei F; Horita H; Masumori N;
    Int J Urol; 2015 Oct; 22(10):911-4. PubMed ID: 26087891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
    Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
    Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical update on palonosetron in the management of chemotherapy-induced nausea and vomiting.
    Celio L; Denaro A; Canova S; Gevorgyan A; Bajetta E
    Tumori; 2008; 94(4):447-52. PubMed ID: 18822676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.
    Piechotta V; Adams A; Haque M; Scheckel B; Kreuzberger N; Monsef I; Jordan K; Kuhr K; Skoetz N
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD012775. PubMed ID: 34784425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of clinical outcomes and efficacy of palonosetron and granisetron in combination with dexamethasone in Egyptian patients receiving highly emetogenic chemotherapy.
    A Mahrous M; A El-Azab G; A Tawfik H
    Cancer Chemother Pharmacol; 2021 Jul; 88(1):121-129. PubMed ID: 33835230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy.
    Longo F; Mansueto G; Lapadula V; De Sanctis R; Quadrini S; Grande R; Gori B; Altavilla A; D'Antoni I; Del Signore E; Stumbo L; De Luca C; Cimadon B; Cortesi E; Gamucci T; Di Seri M
    Support Care Cancer; 2011 Aug; 19(8):1159-64. PubMed ID: 20552375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study.
    Seol YM; Kim HJ; Choi YJ; Lee EM; Kim YS; Oh SY; Koh SJ; Baek JH; Lee WS; Joo YD; Lee HG; Yun EY; Chung JS
    Support Care Cancer; 2016 Feb; 24(2):945-952. PubMed ID: 26265119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Medical treatment of chemotherapy-induced nausea and vomiting].
    Herrstedt J
    Ugeskr Laeger; 2007 Feb; 169(9):799-805. PubMed ID: 17355844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiemetics: American Society of Clinical Oncology clinical practice guideline update.
    Basch E; Prestrud AA; Hesketh PJ; Kris MG; Feyer PC; Somerfield MR; Chesney M; Clark-Snow RA; Flaherty AM; Freundlich B; Morrow G; Rao KV; Schwartz RN; Lyman GH;
    J Clin Oncol; 2011 Nov; 29(31):4189-98. PubMed ID: 21947834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of the combination neurokinin-1 receptor antagonist, palonosetron, and dexamethasone compared to others for the prophylaxis of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials.
    Chow R; Tsao M; Chiu L; Popovic M; Milakovic M; Lam H; DeAngelis C
    Ann Palliat Med; 2018 Apr; 7(2):221-233. PubMed ID: 29764184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting.
    Shirley M
    Drugs; 2021 Jul; 81(11):1331-1342. PubMed ID: 34292534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing antiemetic therapy in multiple-day and multiple cycles of chemotherapy.
    Ellebaek E; Herrstedt J
    Curr Opin Support Palliat Care; 2008 Mar; 2(1):28-34. PubMed ID: 18685391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New antiemetic drugs.
    Roila F; Fatigoni S
    Ann Oncol; 2006 Mar; 17 Suppl 2():ii96-100. PubMed ID: 16608997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiemetic efficacy of single-dose palonosetron and dexamethasone in patients receiving multiple cycles of multiple day-based chemotherapy.
    Lorusso V; Giampaglia M; Petrucelli L; Saracino V; Perrone T; Gnoni A
    Support Care Cancer; 2012 Dec; 20(12):3241-6. PubMed ID: 22534864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Palonosetron: an evidence-based choice in prevention of nausea and vomiting induced by moderately emetogenic chemotherapy.
    Celio L; Agustoni F; Testa I; Dotti K; de Braud F
    Tumori; 2012; 98(3):279-86. PubMed ID: 22825501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
    Rubenstein EB
    Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of antiemesis effects of granisetron, aprepitant and dexamethasone to palonosetron, aprepitant and dexamethasone in treatment of high-emetic risk chemotherapy-induced nausea and vomiting - a retrospective study for efficacy and safety in a single institute].
    Osawa H; Goto H; Myojo T
    Gan To Kagaku Ryoho; 2013 May; 40(5):617-21. PubMed ID: 23863585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.